Physician profile
Daniel E Wenberg
NPI 1376585893
$362.59
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.95 · 2020: $94.30 · 2021: $96.60 · 2022: $90.74.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $150.34 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $87.53 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $45.86 | 2020-2022 | |
| Pfizer INC. | $40.16 | 2019-2021 | |
| Smith+Nephew, INC. | $14.57 | 2020 | |
| Xeris Pharmaceuticals, INC. | $12.24 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.89 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.